Coenzyme Q10 (CoQ10), also known as ubiquinone, is an essential component of the mitochondrial respiratory chain. One of the causes of its deficiency is the chronic use of statins, a class of widely prescribed anti-cholesterolemic drugs. Its reduction can cause undesirable side effects, such as dyspnea, hepatic alterations, muscular and/or gastrointestinal symptoms, rhabdomyolysis, peripheral neuropathies, type 2 Diabetes Mellitus, among others. This literature review aimed to understand whether CoQ10 supplementation reduces the side effects caused by the use of statins, to describe them, and to indicate the safe and effective dose for the success of this nutritional strategy. This is a systematic review of the literature, which was searched in the MEDLINE/PubMed database, of studies published between 2004 and 09/2020, using the descriptors and combination Ubiquinone AND Anticholesteremic Agents and Ubiquinone AND Cholesterol. A total of 462 articles were identified, and after reading the title, abstract, and applying the exclusion criteria, 18 scientific papers were included for analysis. The studies presented varied populations and methodologies, and the methods for evaluating the results were also heterogeneous, mainly due to the variety of side effects studied. Of the 18 studies, ten (66.6%) found some benefit from supplementation. It was evidenced that the usual dose of supplementation (between 100 and 300 mg) was able to bring benefits regarding the following parameters: diastolic, endothelial, and mitochondrial function, fatigue, myopathies, dyspnea, memory loss, peripheral neuropathy, lipid profile, antioxidant and anti-inflammatory activity, and hepatotoxicity evidenced after 30 days of supplementation, and also a reduction in cardiovascular risk.